PPARD and primary biliary cholangitis: ,17 Based on these results, 2 drugs with agonistic effects on PPARD, elafibranor, and seladelpar, were conditionally approved by the Food and Drug Administration (FDA) in the United States as second-line therapy for patients with PBC who do not respond adequately to ursodeoxycholic acid (UDCA).